Triple-negative breast cancer (TNBC) occurs in about 10 to 20% of diagnosed breast cancers and defined by the absence or minimal expression of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) [1,2]. Here, ESR1 is linked to triple-negative breast carcinoma.